ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ETON vs GPCR // GROSS PROFIT MARGIN

Eton Pharmaceuticals Inc. (NASDAQ) VS. Structure Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ETON 4 — GPCR 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ETON VS. GPCR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ETON GPCR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 53.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -0.90% -19.50% +18.60 ETON /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 0.66% -14.43% +15.09 ETON /fcf-yield <GO>
Operating Margin -1.10% — — TIE /operating-margins <GO>
Net Profit Margin -5.80% — — TIE /net-margins <GO>
Revenue Growth (YoY) 104.90% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 13.37 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 1/9 +6.00 ETON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.9 26.5 +21.37 ETON /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.53B $1.56B -$30.5M GPCR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ETON REV GPCR REV ETON GROSS % GPCR GROSS % ETON FCF GPCR FCF
FY 2025 $80.0M $0 53.5% — $10.2M -$225.8M
FY 2024 $39.0M $0 60.0% — $943.0K -$117.9M
FY 2023 $31.6M $0 — — $6.8M -$79.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ETON // BETA —
GPCR // BETA —